A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
about
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerEpidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinomaIncreased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.Targeting the cancer kinome through polypharmacology.ErbB/EGF signaling and EMT in mammary development and breast cancer.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityAnalytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept studyCombating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.Targeted endoscopic imaging.Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of actionTargeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceResistance to Trastuzumab in Breast Cancer.Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancerRole of epidermal growth factor receptor in breast cancer.A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.Safety and feasibility of targeted agent combinations in solid tumours.Biomarkers of drugs targeting HER-family signalling in cancer.Emerging EGFR antagonists for breast cancer.Resistance to EGFR-targeted therapy: a family affair.Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
P2860
Q27025863-F03AC41B-82B7-4C25-AF98-8CDF3356729AQ28543724-5679221D-A421-4E16-8993-80D6DDAE95D6Q30540860-60197FEA-2F4F-4A51-A568-C24F45AADDBEQ33555585-9B9CA5EE-9C38-453D-BFCE-937B4347E9D7Q33893019-0AC5502B-85ED-428A-AC3B-21DB64AD4C2AQ33927493-2891FBAA-BA8D-4F94-9F74-22388F88BAE9Q34036041-AEE74559-FD39-4B8D-962C-1D3D7E18A3C8Q34342079-D4782011-F4E2-4528-960E-6F53B6168297Q34717298-B0453E85-8945-4E69-A395-DDACB274B1D9Q35506684-7BD07BAB-C8AC-4404-B683-DE5C5DD00AEAQ35553821-DD756DB6-1E68-442C-AB70-9302E333B44BQ35559032-3A948C1B-6516-47E0-A819-F34C72079F9EQ35583942-3564FD33-BD9F-4778-ADB2-BE767540201FQ35677713-8D7D072F-4C7F-4CD0-B558-3A678DEE5254Q36250585-36BA4D56-F1C0-4A17-BC65-2BA6DD02AF2EQ36318226-766F8BB9-F395-47DB-BCEF-0429155CA41AQ36551617-3DB02FBB-4DB8-47D2-B7C8-27DEF4077016Q37107395-89DF5EAA-B920-435C-ACAB-33DC57CAE72DQ37320346-384E2E33-10AA-4373-8FC1-8619C1A1CA41Q37418498-8D6C1CC6-2545-45D1-9081-EBD09D52758FQ37459640-4422CB47-5055-440A-BDEF-E3F6374A49F4Q37578368-65287F61-ED50-4A16-BBF3-9355639BA740Q37802782-F7C6736C-3423-479B-B809-6E7DA5546060Q37826199-BD7D8772-2EA6-48A0-9B20-D625308BD8D6Q37863629-58F6FD45-CE3B-4FDB-A6A4-E2B27169F074Q38008847-5D7E71D3-C154-4F9C-94DC-C77792703986Q38077440-58078D8D-5A66-4B9B-B2C7-420038D9A06BQ38150774-1049AF11-241E-4C62-9358-C5F38C53E05BQ38211951-0BB727EA-FA1B-405C-9AE8-F78588DDAA70Q39589553-2CD2BC0F-5D73-4A1B-A2FE-050460A52EC6Q39727725-817D82AD-3B5B-421F-B94B-60C8A84D3AF3Q39845394-5181D983-4397-4489-A61E-59D339E95A4FQ51366224-2A64E504-B151-47A3-A858-D2CA5664CFD5
P2860
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
A phase I-II study of combined ...... sing metastatic breast cancer.
@ast
A phase I-II study of combined ...... sing metastatic breast cancer.
@en
A phase I-II study of combined ...... efitinib in patients with HER2
@nl
type
label
A phase I-II study of combined ...... sing metastatic breast cancer.
@ast
A phase I-II study of combined ...... sing metastatic breast cancer.
@en
A phase I-II study of combined ...... efitinib in patients with HER2
@nl
prefLabel
A phase I-II study of combined ...... sing metastatic breast cancer.
@ast
A phase I-II study of combined ...... sing metastatic breast cancer.
@en
A phase I-II study of combined ...... efitinib in patients with HER2
@nl
P2093
P2860
P1476
A phase I-II study of combined ...... sing metastatic breast cancer.
@en
P2093
Anne O'Neill
Carlos L Arteaga
George W Sledge
Joseph A Sparano
Michael Pins
Nancy E Davidson
Stacy L Moulder
P2860
P304
P356
10.1158/1078-0432.CCR-08-0482
P407
P577
2008-10-01T00:00:00Z